Blockchain Registration Transaction Record

Quantum BioPharma Hits Midpoint in MS Imaging Study with MGH

Quantum BioPharma (QNTM) announces halfway enrollment in MS imaging study with MGH, showing promising PET tracer data for demyelination. Lucid-MS Phase 2 IND submitted.

This news matters because multiple sclerosis affects over 2.8 million people worldwide, and current imaging techniques often miss gray matter lesions, which are critical for disease progression. Quantum BioPharma's novel PET tracer could revolutionize MS diagnosis and treatment monitoring, potentially leading to more effective therapies like Lucid-MS. For investors, the study's positive signals and the company's strategic partnerships (including royalty streams from UNBUZZD) highlight a promising biotech opportunity in a high-need area.